Site Overlay

EINSTEIN PE RIVAROXABAN PDF

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW. Published in , EINSTEIN-PE randomized 4, patients with acute PE to rivaroxaban or standard therapy with enoxaparin and a VKA. Oral, direct Factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis or pulmonary embolism ().

Author: Nikojas Fetaur
Country: Liberia
Language: English (Spanish)
Genre: Relationship
Published (Last): 24 January 2008
Pages: 412
PDF File Size: 19.85 Mb
ePub File Size: 11.27 Mb
ISBN: 428-3-18639-683-5
Downloads: 71923
Price: Free* [*Free Regsitration Required]
Uploader: Vishura

Comparisons are rivaroxaban vs. Views Read View source View history. The principal safety outcome occurred in The bleeding rates were similar in the two study groups, with fewer major bleeding events in the rivaroxaban group. To compare rivaroxaban to standard anticoagulant therapy einsttein enoxaparin and vitamin K antagonist VKA in rivwroxaban treatment of patients with acute symptomatic PE.

The New England Journal of Medicine. To compensate for this, the study used a higher dose during the first 3 weeks of therapy 15mg BID followed by a lower maintenance dose 20mg daily. Among patients with acute PE, rivaroxaban is noninferior to warfarin in preventing recurrent VTE, and is associated with similar bleeding rates.

EINSTEIN-PE

It differed from these studies in several notable ways, however. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. Oral, direct Factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis or pulmonary embolism Major bleeding occured in 1. In addition, its open-label design may have biased both patients and investigators.

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

In a randomized, open-label, event-driven, noninferiority trial involving patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban 15 mg twice daily for rifaroxaban weeks, followed by 20 mg once daily with standard therapy with enoxaparin followed by an rivroxaban vitamin K antagonist for 3, 6, or 12 months.

  FLUKE BC7217 PDF

Usable articles Hematology Pulmonology. For example, the study’s noninferiority design may have rendered it unable to detect small differences in relative efficacy between treatment arms.

The principal safety outcome was major or clinically relevant nonmajor bleeding. Like the others, it employed a noninferiority rather than a superiority design, and enrolled a relatively heterogeneous patient population.

Rates of other adverse einsteiin were similar in the two groups. The primary efficacy outcome was symptomatic recurrent venous thromboembolism.

N Engl J Med. Rivaroxaban was noninferior to standard therapy noninferiority margin, 2. Major bleeding was observed in 26 patients 1.

At a mean follow-up of 7 months, rivaroxaban was noninferior to standard therapy in terms of einstdin rate of recurrent symptomatic VTE rivarlxaban. The outcome of a net clinical benefit occurred in 83 patients 3. A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory monitoring.

It was also one of the first to employ an open-label design lacking matching placebos between groups. Navigation menu Personal tools Create account Log in.

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

This page was last modified on 3 Decemberat N Engl J Med ; Comment in N Rviaroxaban J Med. Randomized, open-label phase III non-inferiority study Active treatment: Rev Clin Esp Barc. Some of these characteristics contribute to the study’s limitations.

  BAJAJ ALLIANZ TWO WHEELER INSURANCE DUPLICATE COPY PDF

A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile.

EINSTEIN-PE – Wiki Journal Club

Retrieved from ” http: This approach may also simplify the treatment of pulmonary embolism. The trial’s generalizability is limited for several reasons, including the fact that 1 patients were younger mean age 58 years than the general acute PE population and 2 the trial excluded patients with cancer. Despite these limitations, there remains a reasonably strong evidence base for rivaroxaban in acute VTE, which led to the FDA approval of rivaroxaban for these indications rivaroxahan November P values are for noninferiority unless otherwise specified.

The bleeding rates were similar in the two study groups, with fewer major bleeding events in the rivaroxaban group Close this section. ESC Guidelines on the diagnosis and management of acute pulmonary embolismadapted: Among patients with acute PE, is rivaroxaban noninferior to warfarin in preventing recurrent VTE or bleeding?

Recommend page Back to top. The fixed dose regimen of rivaroxaban is at least as effective for the initial and long-term treatment of PE as the standard rivarozaban with enoxaparin followed by a VKA Safety: The primary safety endpoint, a first major and clinically relevant non-major bleeding episode, was observed in